Carmustine medac (previously Carmustine Obvius)



This medicine is authorised for use in the European Union.


Carmustine Obvius is a cancer medicine that is used, on its own or with other cancer medicines and treatments, to treat the following types of cancer:

• brain tumours, both those that develop directly in the brain and cancers that have spread from elsewhere in the body (metastatic brain tumours);

• Hodgkin’s lymphoma and non-Hodgkin’s lymphomas, types of cancer that originate from white blood cells. The medicine is used when initial treatment has not worked or the cancer has come back;

• tumours of stomach and bowel;

• malignant melanoma (a type of skin cancer).

Carmustine Obvius is also used as a ‘conditioning’ treatment before transplantation of the patient’s own haematopoietic progenitor cells (immature cells that are able to produce the cells of the blood) to treat Hodgkin’s lymphoma and non-Hodgkin’s lymphomas. It is used to clear the patient’s bone marrow and make room for the transplanted cells.

Carmustine Obvius contains the active substance carmustine and is a ‘generic medicine’. This means that Carmustine Obvius contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Carmubris.

This EPAR was last updated on 14/09/2023

Authorisation details

Product details
Carmustine medac (previously Carmustine Obvius)
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Hodgkin Disease
  • Lymphoma, Non-Hodgkin
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Obvius Investment B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
De Cuserstraat 93
1081 CN Amsterdam

Product information

13/09/2023 Carmustine medac (previously Carmustine Obvius) - EMEA/H/C/004326 - IAIN/0010

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):

  • Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases
  • Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease
  • as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma).

Assessment history

How useful was this page?

Add your rating
2 ratings
4 ratings